Pirfenidone treatment of idiopathic pulmonary fibrosis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Pirfenidone is the first antifibrotic agent to be approved for the treatment of pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) is one of the idiopathic interstitial pneumonias with the worst prognoses; approximately half of patients die within 3–5 years, and the need for an effective treatment has been unmet until recently. The etiology of IPF is still unknown and its pathogenesis is poorly understood. Anti-inflammatory drugs, such as corticosteroids and some immunosuppressants, have been empirically used to treat IPF, although they have not been objectively proven to be effective by large-scale randomized, controlled trials. Pirfenidone is an agent that can inhibit the decline of forced vital capacity (FVC)/vital capacity (VC) and that thereby can be hoped to decrease the mortality rate. The number of clinical trials of pirfenidone completed, ongoing, or planned is growing, and the present status of pirfenidone as treatment for IPF is summarized in this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
King, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531 · cited 2×
“…that the rates of decline in %FVC at week 72 in the placebo-treated group of Study 006 had been lower than those of other groups in Study 006 or a large trial of interferon-γ 1b [King et al. 2009], further strengthening the hypothesis of an attenuated FVC decline in the placebo group in Study 006.”
ResultAntifibrotic activities of pirfenidone in animal models
Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D., & Kossen, K. (2011) · European Respiratory Review · doi:10.1183/09059180.00001111 · Cited by 454 · cited 1×
“These in vivo assays not only demonstrate the antifibrotic activity of pirfenidone in the bleomycin-induced pulmonary fibrosis model, but also in the liver fibrosis, renal sclerosis, and sclerosing dermatosis models [Schaefer et al. 2011].”
Background
Cited by
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis
Walton, K. L., Johnson, K. E., & Harrison, C. A. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00461 · Cited by 543
Conte, E., Gili, E., Fagone, E., Fruciano, M., Iemmolo, M., & Vancheri, C. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.014 · Cited by 368
De Lellis, L., Veschi, S., Tinari, N., Mokini, Z., Carradori, S., Brocco, D., Florio, R., Grassadonia, A., & Cama, A. (2021) · Cancers · doi:10.3390/cancers13163946 · Cited by 40
“Pirfenidone is an orally active and synthetic 2-pyridinone (Figure 1) approved for the treatment of idiopathic pulmonary fibrosis [202].”
Background
Metadata
- Authors
- Azuma, A.
- Venue
- Therapeutic Advances in Respiratory Disease
- Publisher
- SAGE Publications
- Published
- 2012-02-14
- Volume
- 6
- Issue
- 2
- Pages
- 107-114
- ISSN
- 1753-4658 (ISSN-L)
- 1753-4666
- OpenAlex
- W2091120910
- Cited by
- 57
- References
- 2
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pirfenidone treatment of idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1177/1753465812436663
- The paper
- Azuma, A. (2012). Pirfenidone treatment of idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/1753465812436663
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.